EMEA-002633-PIP01-19

Key facts

Active substance
sitravatinib (malate)
Therapeutic area
Oncology
Decision number
P/0416/2019
PIP number
EMEA-002633-PIP01-19
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of non-small cell lung cancer
Route(s) of administration
Oral use
Contact for public enquiries
Mirati Therapeutics, Inc.

E-mail: cheni@mirati.com
Tel.  +1 8583323428

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating